Back to search results

Atebimetinib with GnP for Metastatic Pancreatic Cancer

This study is looking at a new treatment for metastatic pancreatic adenocarcinoma (pancreatic cancer that has spread). It combines a drug called atebimetinib with a standard chemotherapy treatment called GnP (gemcitabine and nab-paclitaxel). Researchers want to see if this combination is safer and more effective than GnP alone. You may be able to join if you are at least 18 years old, have recently been diagnosed with metastatic pancreatic cancer, and have not received other treatments for it. The main goal is to see if the new combination helps people live longer. The current status of the study is unclear, and it plans to enroll 510 participants.

Study design
This is a global, randomized, open-label study, meaning participants will be assigned by chance to one of two treatment groups, and both you and your doctors will know which treatment you are receiving. It plans to enroll 510 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your overall survival will be measured for up to approximately 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07562152

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Recruiting
PHASE3Ages 18+InterventionalTreatment
Immuneering Corporation
~510 participants
Updated 2026-09-11 on ClinicalTrials.gov
What's tested:AtebimetinibGnPmGnP

At a glance

Recruiting sites
45 of 45 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Overall Survival
Measured over Up to approximately 2 years

Conditions

Pancreatic Cancer
Pancreatic Cancer Metastatic
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Pancreatic Adenocarcinoma Metastatic
Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic Adenocarcinoma

Explore related trials

Pancreatic Adenocarcinoma

NCT07562152

Where you'd take part

This study runs at 45 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Avera Cancer Institute Research

    Sioux Falls, South Dakotastudy coordinator listed

    Recruiting

  • Bayside Health

    Frankston East, Victoria, Australiastudy coordinator listed

    Recruiting

  • Blue Ridge Cancer Care

    Blacksburg, Virginiastudy coordinator listed

    Recruiting

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australiastudy coordinator listed

    Recruiting

  • Cancer Research South Australia

    Adelaide, South Australia, Australiastudy coordinator listed

    Recruiting

  • City of Hope

    Phoenix, Arizonastudy coordinator listed

    Recruiting

  • City of Hope

    Duarte, Californiastudy coordinator listed

    Recruiting

  • City of Hope

    Chicago, Illinoisstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Immuneering Study Team
[email protected]
860-321-1302
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Must be ≥18 years of age
Must have confirmed diagnosis according to AJCC staging as follows:
Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Participants must be treatment naive as follows:
First-line PDAC participants will have received no previous systemic anti-cancer therapy
Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria
Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values

Exclusion

Inability to swallow oral medications
Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
Participants with only locally advanced disease
Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases

What this trial measures

  • Overall SurvivalUp to approximately 2 years

    The OS of participants with atebimetinib in combination with mGnP versus GnP